Hansa Biopharma AB (HNSAN) Ratios
Hansa Biopharma AB Ratios
MX:HNSAN's free cash flow for Q2 2026 was $-122.05M. For the 2026 fiscal year, MX:HNSAN's free cash flow was decreased by $-18.54M and operating cash flow was $-103.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.94 | 2.29 | 2.66 | 6.06 | 5.50 |
| Quick Ratio | 1.92 | 2.28 | 2.66 | 6.06 | 5.50 |
| Cash Ratio | 1.71 | 1.59 | 2.28 | 5.65 | 3.80 |
| Solvency Ratio | -0.40 | -0.56 | -0.69 | -0.55 | -2.11 |
| Operating Cash Flow Ratio | -1.34 | -2.64 | -2.35 | -1.90 | -2.81 |
| Short-Term Operating Cash Flow Coverage | -4.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -454.29M | $ -805.05M | $ -330.77M | $ 520.21M | $ 687.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.80 | 1.35 | 0.85 | 0.47 | 0.03 |
| Debt-to-Equity Ratio | -10.49 | -1.83 | -5.16 | 1.31 | 0.05 |
| Debt-to-Capital Ratio | 1.11 | 2.21 | 1.24 | 0.57 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 1.13 | 2.24 | 1.25 | 0.56 | 0.00 |
| Financial Leverage Ratio | -13.11 | -1.36 | -6.06 | 2.80 | 1.34 |
| Debt Service Coverage Ratio | -1.91 | -4.81 | -6.78 | -12.72 | -776.63 |
| Interest Coverage Ratio | -4.43 | -4.76 | -7.47 | -13.19 | -777.49 |
| Debt to Market Cap | 0.33 | 0.43 | 0.61 | 0.34 | 0.00 |
| Interest Debt Per Share | 12.95 | 19.31 | 18.51 | 18.58 | 0.81 |
| Net Debt to EBITDA | -0.48 | -1.05 | -0.19 | 1.27 | 1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.41% | 51.23% | 52.91% | 75.10% | 54.47% |
| EBIT Margin | -235.11% | -391.17% | -540.88% | -366.49% | -1615.90% |
| EBITDA Margin | -217.68% | -374.79% | -532.88% | -358.69% | -1590.50% |
| Operating Profit Margin | -234.27% | -372.34% | -588.02% | -372.83% | -1592.72% |
| Pretax Profit Margin | -239.28% | -469.43% | -619.57% | -394.74% | -1617.95% |
| Net Profit Margin | -240.30% | -471.20% | -620.25% | -395.49% | -1618.40% |
| Continuous Operations Profit Margin | -240.30% | -471.20% | -620.25% | -395.49% | -1618.40% |
| Net Income Per EBT | 100.43% | 100.38% | 100.11% | 100.19% | 100.03% |
| EBT Per EBIT | 102.14% | 126.08% | 105.37% | 105.88% | 101.58% |
| Return on Assets (ROA) | -45.78% | -100.82% | -81.70% | -36.22% | -54.13% |
| Return on Equity (ROE) | 600.18% | 136.86% | 495.44% | -101.36% | -72.37% |
| Return on Capital Employed (ROCE) | -68.87% | -117.05% | -113.12% | -40.50% | -64.11% |
| Return on Invested Capital (ROIC) | -57.78% | -115.42% | -111.91% | -40.29% | -63.59% |
| Return on Tangible Assets | -57.05% | -133.80% | -94.28% | -37.25% | -55.72% |
| Earnings Yield | -19.14% | -32.77% | -60.42% | -27.64% | -13.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.49 | 1.17 | 1.72 | 2.38 | 3.04 |
| Payables Turnover | 1.26 | 2.22 | 0.73 | 0.62 | 0.29 |
| Inventory Turnover | 13.63 | 32.01 | 41.73 | 39.54 | 63.74 |
| Fixed Asset Turnover | 16.65 | 9.58 | 4.95 | 4.31 | 0.74 |
| Asset Turnover | 0.19 | 0.21 | 0.13 | 0.09 | 0.03 |
| Working Capital Turnover Ratio | 0.62 | 0.40 | 0.14 | 0.15 | 0.03 |
| Cash Conversion Cycle | -115.95 | 158.82 | -281.58 | -429.87 | -1137.00 |
| Days of Sales Outstanding | 146.80 | 311.77 | 212.38 | 153.56 | 119.92 |
| Days of Inventory Outstanding | 26.79 | 11.40 | 8.75 | 9.23 | 5.73 |
| Days of Payables Outstanding | 289.54 | 164.35 | 502.71 | 592.66 | 1262.65 |
| Operating Cycle | 173.59 | 323.17 | 221.13 | 162.79 | 125.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.76 | -10.74 | -14.38 | -11.19 | -10.82 |
| Free Cash Flow Per Share | -6.76 | -10.74 | -14.39 | -11.26 | -10.87 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -5817.97 | -2660.75 | -150.93 | -200.57 |
| Capital Expenditure Coverage Ratio | 0.00 | -5817.97 | -2660.75 | -150.93 | -200.57 |
| Operating Cash Flow Coverage Ratio | -0.59 | -0.63 | -0.87 | -0.64 | -13.60 |
| Operating Cash Flow to Sales Ratio | -2.47 | -3.94 | -5.64 | -3.25 | -14.20 |
| Free Cash Flow Yield | -19.68% | -27.40% | -54.92% | -22.89% | -12.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.22 | -3.05 | -1.66 | -3.62 | -7.20 |
| Price-to-Sales (P/S) Ratio | 12.55 | 14.38 | 10.27 | 14.31 | 116.57 |
| Price-to-Book (P/B) Ratio | -31.35 | -4.18 | -8.20 | 3.67 | 5.21 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.08 | -3.65 | -1.82 | -4.37 | -8.17 |
| Price-to-Operating Cash Flow Ratio | -5.08 | -3.65 | -1.82 | -4.40 | -8.21 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | 0.16 | -0.10 | -0.35 | -0.31 |
| Enterprise Value Multiple | -6.25 | -4.89 | -2.11 | -2.72 | -6.19 |
| Enterprise Value | 3.02B | 3.14B | 1.51B | 1.51B | 3.33B |
| EV to EBITDA | -6.25 | -4.89 | -2.11 | -2.72 | -6.19 |
| EV to Sales | 13.60 | 18.31 | 11.27 | 9.75 | 98.39 |
| EV to Free Cash Flow | -5.50 | -4.65 | -2.00 | -2.98 | -6.89 |
| EV to Operating Cash Flow | -5.50 | -4.65 | -2.00 | -3.00 | -6.93 |
| Tangible Book Value Per Share | -3.88 | -12.53 | -5.78 | 12.38 | 16.39 |
| Shareholders’ Equity Per Share | -1.10 | -9.39 | -3.20 | 13.42 | 17.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 2.74 | 2.73 | 2.55 | 3.44 | 0.76 |
| Net Income Per Share | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.20 | 1.15 | 1.08 | 1.00 |
| Research & Development to Revenue | 1.37 | 2.19 | 3.07 | 2.24 | 6.81 |
| SG&A to Revenue | 1.60 | 2.01 | 3.36 | 2.19 | 9.66 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.38 | 1.67 |
| Income Quality | 1.04 | 0.84 | 0.91 | 0.82 | 0.88 |
Currency in SEK
